Metabolite profiling of blood plasma of patients with prostate cancer

Metabolomics

Volumn 6, Issue 1, 2010, Pages 156-163

  Lokhov, Petr G ^a   Dashtiev, Maxim I ^b   Moshkovskii, Sergey A ^a   Archakov, Alexander I ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^b Bruker Ltd   (Russian Federation)

Author keywords

Blood plasma metabolites; Mass spectrometry; Prostate cancer

Indexed keywords

EID: 77949310048     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-009-0187-x     Document Type: Article

References (47)

1. Ahmed, F. E. (2009). Sample preparation and fractionation for proteome analysis and cancer biomarker discovery by mass spectrometry. Journal of Separation Science, 32, 771-798.
2. Beecher, C. W. W. (2003). Metabolic profiling: Its role in biomarker discovery and gene function analysis (pp. 311-335). New York: Springer.
3. Carini, C. (2007). Biomarkers: A valuable tool in clinical research and medical practice. IDrugs, 10, 395-398.
4. Carter, A. L., Hutson, S. M., Stratman, F. W., & Haning, R. V., Jr. (1980). Relationship of carnitine and acylcarnitines in ejaculated sperm to blood plasma testosterone of dairy bulls. Biology of Reproduction, 23, 820-825.
5. Chace, D. H., & Kalas, T. A. (2005). A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing. Clinical Biochemistry, 38, 296-309.
6. Chace, D. H., Kalas, T. A., & Naylor, E. W. (2002). The application of tandem mass spectrometry to neonatal screening for inherited disorders of intermediary metabolism. Annual Review of Genomics and Human Genetics, 3, 17-45.
7. Chace, D. H., Kalas, T. A., & Naylor, E. W. (2003). Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clinical Chemistry, 49, 1797-1817.
8. Cho, S. H., Choi, M. H., Lee, W. Y., & Chung, B. C. (2009). Evaluation of urinary nucleosides in breast cancer patients before and after tumor removal. Clinical Biochemistry, 42, 540-543.
9. Dettmer, K., Aronov, P. A., & Hammock, B. D. (2007). Mass spectrometry-based metabolomics. Mass Spectrometry Reviews, 26, 51-78.
10. Dizeyi, N., Bjartell, A., Nilsson, E., et al. (2004). Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate, 59, 328-336.
11. Emilien, G., Ponchon, M., Caldas, C., Isacson, O., & Maloteaux, J. M. (2000). Impact of genomics on drug discovery and clinical medicine. QJM, 93, 391-423.
12. German, J. B., Roberts, M. A., & Watkins, S. M. (2003). Genomics and metabolomics as markers for the interaction of diet and health: Lessons from lipids. Journal of Nutrition, 133, 2078-2083.
13. Gowda, G. A., Zhang, S., Gu, H., Asiago, V., Shanaiah, N., & Raftery, D. (2008). Metabolomics-based methods for early disease diagnostics. Expert Review of Molecular Diagnostics, 8, 617-633.
14. Hankey, B. F., Feuer, E. J., Clegg, L. X., et al. (1999). Cancer surveillance series: Interpreting trends in prostate cancer. Part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. Journal of the National Cancer Institute, 91, 1017-1024.
15. He, Q. Y., & Chiu, J. F. (2003). Proteomics in biomarker discovery and drug development. Journal of Cellular Biochemistry, 89, 868-886.
16. Hsu, W. Y., Chen, W. T., Lin, W. D., et al. (2009). Analysis of urinary nucleosides as potential tumor markers in human colorectal cancer by high performance liquid chromatography/electrospray ionization tandem mass spectrometry. Clinica Chimica Acta, 402, 31-37.
17. IARC Worldwide Cancer Incidence Statistics-Prostate. (2001). JNCI cancer spectrum (Vol. 19). Oxford University Press.
18. Imamoto, T., Suzuki, H., Fukasawa, S., et al. (2005). Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. European Urology, 47, 308-312.
19. Isbarn, H., Pinthus, J. H., Marks, L. S., et al. (2009). Testosterone and prostate cancer: Revisiting old paradigms. European Urology, 56, 48-56.
20. Jemal, A., Tiwari, R. C., Murray, T., et al. (2004). Cancer Statistics, 2004. CA: A Cancer Journal for Clinicians, 54, 8-29.
21. Lai, H. S., Lee, J. C., Lee, P. H., Wang, S. T., & Chen, W. J. (2005). Plasma free amino acid profile in cancer patients. Seminars in Cancer Biology, 15, 267-276.
22. Lein, M., Kwiatkowski, M., Semjonow, A., et al. (2003). A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. Journal of Urology, 170, 1175-1179.
23. Malaguarnera, M., Risino, C., Gargante, M. P., et al. (2006). Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. World Journal of Gastroenterology, 12, 4541-4545.
24. Marquis, N. R., & Fritz, I. B. (1965). Effects of testosterone on the distribution of carnitine, acetylcarnitine, and carnitine acetyltransferase in tissues of the reproductive system of the male rat. Journal of Biological Chemistry, 240, 2197-2200.
25. Metz, C. E. (1978). Basic principles of ROC analysis. Seminars in Nuclear Medicine, 8, 283-298.
26. Morgentaler, A., Bruning, C. O., III, & DeWolf, W. C. (1996). Occult prostate cancer in men with low serum testosterone levels. Journal of the American Medical Association, 276, 1904-1906.
27. Morgentaler, A., & Rhoden, E. L. (2006). Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4. 0 ng/mL or less. Urology, 68, 1263-1267.
28. Murph, M., Tanaka, T., Pang, J., et al. (2007). Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: Potential biomarkers for cancer diagnosis. Methods in Enzymology, 433, 1-25.
29. Ohshima, A., Cohen, B. I., Ayyad, N., & Mosbach, E. H. (1996). Effect of a synthetic androgen on biliary lipid secretion in the female hamster. Lipids, 31, 879-886.
30. Osl, M., Dreiseitl, S., Pfeifer, B., et al. (2008). A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry. Bioinformatics, 24, 2908-2914.
31. Piraud, M., Vianey-Saban, C., Petritis, K., et al. (2003). ESI-MS/MS analysis of underivatised amino acids: A new tool for the diagnosis of inherited disorders of amino acid metabolism. Fragmentation study of 79 molecules of biological interest in positive and negative ionisation mode. Rapid Communications in Mass Spectrometry, 17, 1297-1311.
32. Rajcevic, U., Niclou, S. P., & Jimenez, C. R. (2009). Proteomics strategies for target identification and biomarker discovery in cancer. Frontiers in Bioscience, 14, 3292-32303.
33. Raynaud, J. P. (2009). Testosterone deficiency syndrome: Treatment and cancer risk. Journal of Steroid Biochemistry and Molecular Biology, 114, 96-105.
34. Rhoden, E. L., Riedner, C. E., & Morgentaler, A. (2008). The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men. Journal of Urology, 179, 1741-1744.
35. Sachan, D. S., & Dodson, W. L. (1987). The serum carnitine status of cancer patients. Journal of the American College of Nutrition, 6, 145-150.
36. Schatzl, G., Madersbacher, S., Thurridl, T., et al. (2001). High-grade prostate cancer is associated with low serum testosterone levels. Prostate, 47, 52-58.
37. Schulze, A., Lindner, M., Kohlmuller, D., Olgemoller, K., Mayatepek, E., & Hoffmann, G. F. (2003). Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: Results, outcome, and implications. Pediatrics, 111, 1399-1406.
38. Seo, D., & Ginsburg, G. S. (2005). Genomic medicine: Bringing biomarkers to clinical medicine. Current Opinion in Chemical Biology, 9, 381-386.
39. Siddiqui, E. J., Shabbir, M., Mikhailidis, D. P., Thompson, C. S., & Mumtaz, F. H. (2006). The role of serotonin (5-hydroxytryptamine 1A and 1B) receptors in prostate cancer cell proliferation. Journal of Urology, 176, 1648-1653.
40. Smith, C. A., O'Maille, G., Want, E. J., et al. (2005). METLIN: A metabolite mass spectral database. Therapeutic Drug Monitoring, 27, 747-751.
41. Sreekumar, A., Poisson, L. M., Rajendiran, T. M., et al. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 457, 910-914.
42. Taylor, B. S., Pal, M., Yu, J., et al. (2008). Humoral response profiling reveals pathways to prostate cancer progression. Molecular & Cellular Proteomics, 7, 600-611.
43. Vinci, E., Rampello, E., Zanoli, L., Oreste, G., Pistone, G., & Malaguarnera, M. (2005). Serum carnitine levels in patients with tumoral cachexia. European Journal of Internal Medicine, 16, 419-423.
44. Wishart, D. S., Tzur, D., Knox, C., et al. (2007). HMDB: The Human Metabolome Database. Nucleic Acids Research (Database issue), 35, D521-D526.
45. Xue, R., Lin, Z., Deng, C., et al. (2008). A serum metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed by gas chromatography/mass spectrometry. Rapid Communications in Mass Spectrometry, 22, 3061-3068.
46. Yano, M., Imamoto, T., Suzuki, H., et al. (2007). The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. European Urology, 51, 375-380.
47. Zheng, Y. F., Yang, J., Zhao, X. J., et al. (2005). Urinary nucleosides as biological markers for patients with colorectal cancer. World Journal of Gastroenterology, 11, 3871-3876.